{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:52:32Z","timestamp":1790801552148,"version":"4.1.0"},"reference-count":63,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of patients with plaque psoriasis. The main objective of this systematic review was to review all cases of eczema, including atopic eczema, reported in patients treated with biologics for chronic plaque psoriasis. PubMed, Medline and Embase databases were used to identify studies reporting eczema in patients treated with biologic therapy for chronic plaque psoriasis. A total of 92 patients were identified from 24 studies, with patients treated with either: adalimumab; etanercept; infliximab; ixekizumab; secukinumab; or ustekinumab. Factors common to some reported cases include: a prior history of atopy; eosinophilia; raised serum immunoglobulin E. Twenty\u2010three had documented treatment outcomes; 14 had biologic therapy discontinued or switched. Management strategies included topical or oral corticosteroids, and treatment with alternative systemic agents such as ciclosporin or apremilast. This adverse event occurred in 1.0\u201312.1% of patients within trial data and observational studies. This review demonstrates that there are consistent reports of a switch to an atopic eczema phenotype from psoriasis in patients taking biologics inhibiting tumour necrosis factor alpha and the interleukin (<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>)\u201017\/<jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\u201023 axis. The majority stopped the implicated biologic, but conservative management was successful in some cases. Those with an atopic diathesis may be more at risk. Elucidation of mechanisms and risk factors would contribute to optimal therapy selection for individual patients.<\/jats:p>","DOI":"10.1111\/jdv.16246","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T08:32:26Z","timestamp":1580373146000},"page":"1440-1448","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review"],"prefix":"10.1111","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-0556","authenticated-orcid":false,"given":"A.","family":"Al\u2010Janabi","sequence":"first","affiliation":[{"name":"The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre Manchester UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Foulkes","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre Manchester UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mason","sequence":"additional","affiliation":[{"name":"Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St John's Institute of Dermatology School of Basic and Medical Biosciences Faculty of Life Sciences and Medicine King's College London London UK"},{"name":"St. John's Institute of Dermatology Guy's and St Thomas\u2019 NHS Foundation Trust London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre Manchester UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.B.","family":"Warren","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Salford Royal NHS Foundation Trust Manchester NIHR Biomedical Research Centre Manchester Academic Health Science Centre Manchester UK"},{"name":"Division of Musculoskeletal and Dermatological Sciences School of Biological Sciences Faculty of Biology, Medicine and Health The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.10.015"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.2.223"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14295"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2014.12.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08514.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17779"},{"issue":"1","key":"e_1_2_7_10_1","first-page":"AB180","article-title":"Eczema\u2010like reactions induced by tumor necrosis factor\u2010alfa antagonist agents","volume":"68","author":"Arevalo MP","year":"2013","journal-title":"Journal of the American Academy of Dermatology Conference: 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL United States Conference Publication"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12751"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02165.x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2012.586"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"P003","article-title":"Erythroderma following ustekinumab therapy for psoriasis","volume":"179","author":"Dhonncha EN","year":"2018","journal-title":"British Journal of Dermatology Conference: 98th Annual Meeting of the British Association of Dermatologists, BAD"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000356776"},{"key":"e_1_2_7_16_1","first-page":"315","article-title":"Counter\u2010regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy","volume":"3","author":"Chan JL","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2015.06.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15156"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.026"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104200"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510017968"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0729"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10835.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02935.x"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591576505800503"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2010.07.022"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000235582"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2015.1125524"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000088"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2006.01058.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1230173"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1724"},{"issue":"3","key":"e_1_2_7_34_1","first-page":"A1","article-title":"Anti\u2010TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors","volume":"59","author":"Cleynen I","year":"2010","journal-title":"Gut"},{"key":"e_1_2_7_35_1","first-page":"12","article-title":"Atopic dermatitis as a side effect of anti\u2010TNFa","volume":"24","author":"Pires MC","year":"2013","journal-title":"Annual American Contact Dermatitis Society, ACDS Meeting"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740701288173"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06282.x"},{"key":"e_1_2_7_38_1","first-page":"28","article-title":"Asthma\u2010like symptoms in a patient with rheumatoid arthritis and Adalimumab treatment","volume":"64","author":"Margineanu I","year":"2015","journal-title":"Pneumologia"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh676"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2012.1816"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.014"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13901"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18031"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13112"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.11.022"},{"key":"e_1_2_7_47_1","unstructured":"National Library of Medicine (US).ClinicalTrials.gov [Internet].Bethesda MD:National Library of Medicine (US).2000. Identifier NCT02594098 Secukinumab for Treatment of Atopic Dermatitis; 2015 Nov 2. [WWW document]https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02594098(last accessed: 5 January 2020)."},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555924447"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16126"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1290\/0501008.1"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.02.037"},{"key":"e_1_2_7_54_1","unstructured":"National Library of Medicine (US).ClinicalTrials.gov [Internet].Bethesda MD:National Library of Medicine (US).2000. Identifier NCT03568071 A Study to Assess Efficacy Safety Tolerability and Pharmacokinetics (PK)\/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis; 2018 Jun 25. [WWW document]https:\/\/clinicaltrials.gov\/show\/NCT03568071(last accessed: 7 July 2019)."},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt317"},{"key":"e_1_2_7_56_1","first-page":"273","article-title":"Adverse reactions during biological drug therapy in psoriasis: clinical series and a review of the literature","volume":"146","author":"Montesu MA","year":"2011","journal-title":"G Ital Dermatol Venereol"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04199.x"},{"issue":"4","key":"e_1_2_7_58_1","first-page":"27","article-title":"Cutaneous reactions in biological treatments","volume":"24","author":"Garcia\u2010Bustinduy MC","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology Conference: 3rd International Congress on Psoriasis"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09986.x"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16736"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0520-z"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.16246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.16246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.16246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T18:32:02Z","timestamp":1693938722000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.16246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/jdv.16246"],"URL":"https:\/\/doi.org\/10.1111\/jdv.16246","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2019-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}